COLL (Collegium Pharmaceutical, Inc.) Stock Financials & Earnings

COLLCollegium Pharmaceutical, Inc.

Mkt Cap$1B

Revenue (TTM)$781M

Net Income (TTM)$63M

EPS (TTM)$1.71

Free Cash Flow (TTM)$328M

Gross Margin59.3%

Op. Margin23.0%

Net Margin8.1%

FCF Margin42.0%

P/S Ratio (TTM)1.5x

P/E Ratio (TTM)18.9x

YoY Rev Growth+23.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$145M	$77M	$25M
Q2 23	$136M	$74M	$36M
Q3 23	$137M	$80M	$45M
Q4 23	$150M	$95M	$62M
Q1 24	$145M	$91M	$49M
Q2 24	$145M	$91M	$47M
Q3 24	$159M	$97M	$35M
Q4 24	$182M	$98M	$38M
Q1 25	$178M	$97M	$22M
Q2 25	$188M	$108M	$35M
Q3 25	$209M	$129M	$64M
Q4 25	$205M	$128M	$59M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	G&A	S&M	SG&A
Q1 23	—	—	$53M
Q2 23	—	—	$38M
Q3 23	—	—	$35M
Q4 23	$26M	$7M	—
Q1 24	—	—	$42M
Q2 24	—	—	$43M
Q3 24	—	—	$62M
Q4 24	—	—	$63M
Q1 25	—	—	$76M
Q2 25	—	—	$74M
Q3 25	—	—	$66M
Q4 25	—	—	$68M

Revenue Segments

Quarter	Belbuca	Nucynta ER	Nucynta IR	Symproic	Xtampza ER
Q1 23	$44M	$21M	$28M	$4M	$48M
Q2 23	$43M	$19M	$28M	$4M	$41M
Q3 23	$45M	$23M	$25M	$4M	$40M
Q1 24	$51M	$19M	$26M	$3M	$46M
Q2 24	$52M	$19M	$25M	$4M	$45M
Q3 24	$53M	$20M	$25M	$4M	$49M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$269M	$0	$269M
Q2 23	$284M	$42M	$325M
Q3 23	$259M	$46M	$305M
Q4 23	$239M	$72M	$311M
Q1 24	$229M	$89M	$318M
Q2 24	$173M	$99M	$272M
Q3 24	$39M	$81M	$120M
Q4 24	$71M	$92M	$163M
Q1 25	$96M	$102M	$198M
Q2 25	$117M	$105M	$222M
Q3 25	$170M	$136M	$306M
Q4 25	$251M	$155M	$407M

Shares Outstanding

Revenue Per Employee

Revenue / Employee